nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Paranoia—Varenicline—nicotine dependence	0.0548	0.139	CcSEcCtD
Trihexyphenidyl—Delusion—Varenicline—nicotine dependence	0.0528	0.134	CcSEcCtD
Trihexyphenidyl—Mydriasis—Varenicline—nicotine dependence	0.0468	0.119	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Varenicline—nicotine dependence	0.0321	0.0815	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Varenicline—nicotine dependence	0.0265	0.0672	CcSEcCtD
Trihexyphenidyl—Dry skin—Varenicline—nicotine dependence	0.0249	0.0631	CcSEcCtD
Trihexyphenidyl—CHRM4—Monoamine GPCRs—DRD2—nicotine dependence	0.0201	0.0332	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Monoamine GPCRs—DRD2—nicotine dependence	0.0193	0.0318	CbGpPWpGaD
Trihexyphenidyl—Hallucination—Varenicline—nicotine dependence	0.0187	0.0474	CcSEcCtD
Trihexyphenidyl—CHRM4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0169	0.0279	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0162	0.0267	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0155	0.0256	CbGpPWpGaD
Trihexyphenidyl—Vision blurred—Varenicline—nicotine dependence	0.0154	0.0391	CcSEcCtD
Trihexyphenidyl—Agitation—Varenicline—nicotine dependence	0.015	0.0381	CcSEcCtD
Trihexyphenidyl—CHRM5—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0149	0.0245	CbGpPWpGaD
Trihexyphenidyl—CHRM4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.0137	0.0227	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.0136	0.0224	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.0135	0.0223	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Monoamine GPCRs—DRD2—nicotine dependence	0.0134	0.0221	CbGpPWpGaD
Trihexyphenidyl—Tachycardia—Varenicline—nicotine dependence	0.013	0.033	CcSEcCtD
Trihexyphenidyl—Somnolence—Varenicline—nicotine dependence	0.0118	0.0301	CcSEcCtD
Trihexyphenidyl—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0114	0.0188	CbGpPWpGaD
Trihexyphenidyl—Constipation—Varenicline—nicotine dependence	0.0114	0.0289	CcSEcCtD
Trihexyphenidyl—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0114	0.0188	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0113	0.0186	CbGpPWpGaD
Trihexyphenidyl—Feeling abnormal—Varenicline—nicotine dependence	0.011	0.0279	CcSEcCtD
Trihexyphenidyl—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0105	0.0173	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0104	0.0172	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0103	0.017	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00966	0.0159	CbGpPWpGaD
Trihexyphenidyl—Asthenia—Varenicline—nicotine dependence	0.00956	0.0243	CcSEcCtD
Trihexyphenidyl—CHRM4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00926	0.0153	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00925	0.0153	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00914	0.0151	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00886	0.0146	CbGpPWpGaD
Trihexyphenidyl—Dizziness—Varenicline—nicotine dependence	0.00881	0.0224	CcSEcCtD
Trihexyphenidyl—Vomiting—Varenicline—nicotine dependence	0.00847	0.0215	CcSEcCtD
Trihexyphenidyl—Rash—Varenicline—nicotine dependence	0.0084	0.0213	CcSEcCtD
Trihexyphenidyl—Dermatitis—Varenicline—nicotine dependence	0.00839	0.0213	CcSEcCtD
Trihexyphenidyl—Headache—Varenicline—nicotine dependence	0.00835	0.0212	CcSEcCtD
Trihexyphenidyl—CHRM4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00831	0.0137	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00796	0.0131	CbGpPWpGaD
Trihexyphenidyl—Nausea—Varenicline—nicotine dependence	0.00792	0.0201	CcSEcCtD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00784	0.0129	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00651	0.0107	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00649	0.0107	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00643	0.0106	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00624	0.0103	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00622	0.0103	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00616	0.0102	CbGpPWpGaD
Trihexyphenidyl—CHRM4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00579	0.00955	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00561	0.00925	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.00559	0.00922	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00553	0.00913	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00537	0.00886	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00523	0.00863	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00514	0.00849	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00475	0.00783	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0047	0.00775	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0046	0.00759	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0045	0.00742	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00441	0.00727	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00432	0.00714	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—TAS2R16—nicotine dependence	0.00427	0.00704	CbGpPWpGaD
Trihexyphenidyl—CHRM4—G alpha (i) signalling events—DRD2—nicotine dependence	0.00419	0.00691	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—TAS2R16—nicotine dependence	0.00409	0.00674	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00388	0.00641	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00385	0.00636	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00372	0.00614	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—FGD1—nicotine dependence	0.00369	0.00608	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00362	0.00598	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00361	0.00596	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00358	0.0059	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—FGD1—nicotine dependence	0.00353	0.00583	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—OPRM1—nicotine dependence	0.0035	0.00578	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—OPRM1—nicotine dependence	0.00336	0.00554	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—FGD1—nicotine dependence	0.00335	0.00552	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00333	0.00549	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—FGD1—nicotine dependence	0.00321	0.00529	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.0032	0.00528	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00319	0.00526	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00317	0.00523	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00316	0.00521	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00313	0.00516	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0031	0.00512	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00309	0.0051	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00306	0.00506	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00288	0.00475	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.00287	0.00473	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.00284	0.00469	CbGpPWpGaD
Trihexyphenidyl—CHRM2—G alpha (i) signalling events—DRD2—nicotine dependence	0.00279	0.0046	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00262	0.00432	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00261	0.00431	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00259	0.00427	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—DRD2—nicotine dependence	0.00253	0.00418	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TAS2R16—nicotine dependence	0.00252	0.00416	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.00249	0.0041	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.00248	0.00409	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—FGD1—nicotine dependence	0.00245	0.00405	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—DRD2—nicotine dependence	0.00243	0.004	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TAS2R16—nicotine dependence	0.00241	0.00398	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.00236	0.0039	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.00236	0.00389	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—OPRM1—nicotine dependence	0.00233	0.00385	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.00226	0.00373	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.00225	0.00371	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00224	0.0037	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00224	0.00369	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—FGD1—nicotine dependence	0.00223	0.00368	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00221	0.00365	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—OPRM1—nicotine dependence	0.00198	0.00327	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—FGD1—nicotine dependence	0.00198	0.00326	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—OPRM1—nicotine dependence	0.0019	0.00313	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—FGD1—nicotine dependence	0.00189	0.00313	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—OPRM1—nicotine dependence	0.0018	0.00297	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKR1B10—nicotine dependence	0.00175	0.00288	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—OPRM1—nicotine dependence	0.00172	0.00284	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.00171	0.00282	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.0017	0.00281	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.0017	0.0028	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.00169	0.0028	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—DRD2—nicotine dependence	0.00169	0.00278	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TAS2R16—nicotine dependence	0.00168	0.00277	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKR1B10—nicotine dependence	0.00167	0.00276	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—DRD2—nicotine dependence	0.00143	0.00236	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—DRD2—nicotine dependence	0.00137	0.00226	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00134	0.0022	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.00133	0.0022	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.00133	0.0022	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.00133	0.00219	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—OPRM1—nicotine dependence	0.00132	0.00218	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGD1—nicotine dependence	0.00132	0.00217	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.00131	0.00215	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—DRD2—nicotine dependence	0.0013	0.00215	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—DRD2—nicotine dependence	0.00125	0.00205	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—WASF2—nicotine dependence	0.00123	0.00203	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.00121	0.002	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.00121	0.00199	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—OPRM1—nicotine dependence	0.0012	0.00198	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—WASF1—nicotine dependence	0.00118	0.00195	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—WASF2—nicotine dependence	0.00118	0.00195	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.00118	0.00194	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.00117	0.00194	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKR1B10—nicotine dependence	0.00116	0.00192	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—WASF1—nicotine dependence	0.00113	0.00186	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—OPRM1—nicotine dependence	0.00106	0.00175	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—OPRM1—nicotine dependence	0.00102	0.00168	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000966	0.00159	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000962	0.00159	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—DRD2—nicotine dependence	0.000953	0.00157	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000877	0.00145	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.000874	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—DRD2—nicotine dependence	0.000866	0.00143	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.00083	0.00137	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000827	0.00137	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—WASF2—nicotine dependence	0.000819	0.00135	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000796	0.00131	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000793	0.00131	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—WASF1—nicotine dependence	0.000785	0.0013	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—DRD2—nicotine dependence	0.000768	0.00127	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—DRD2—nicotine dependence	0.000736	0.00121	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.000716	0.00118	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000714	0.00118	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—OPRM1—nicotine dependence	0.000707	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—DRD2—nicotine dependence	0.000518	0.000855	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—DRD2—nicotine dependence	0.000516	0.000852	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—DRD2—nicotine dependence	0.000511	0.000844	CbGpPWpGaD
